These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28445541)

  • 21. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
    Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
    Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IQGAP1 is a scaffold for mitogen-activated protein kinase signaling.
    Roy M; Li Z; Sacks DB
    Mol Cell Biol; 2005 Sep; 25(18):7940-52. PubMed ID: 16135787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction.
    Pan CW; Jin X; Zhao Y; Pan Y; Yang J; Karnes RJ; Zhang J; Wang L; Huang H
    EMBO J; 2017 Apr; 36(8):995-1010. PubMed ID: 28279977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Ras GTPase-activating-like protein IQGAP1 is downregulated in human diabetic nephropathy and associated with ERK1/2 pathway activation.
    Zhou H; Yao C; Bian A; Qian J; Zhao X; Zhao Y; Wang W; Xing C
    Mol Cell Biochem; 2014 Jun; 391(1-2):21-5. PubMed ID: 24488174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IQGAP1 plays an important role in the cell proliferation of multiple myeloma via the MAP kinase (ERK) pathway.
    Ma Y; Jin Z; Huang J; Zhou S; Ye H; Jiang S; Yu K
    Oncol Rep; 2013 Dec; 30(6):3032-8. PubMed ID: 24101133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The WW domain of the scaffolding protein IQGAP1 is neither necessary nor sufficient for binding to the MAPKs ERK1 and ERK2.
    Bardwell AJ; Lagunes L; Zebarjedi R; Bardwell L
    J Biol Chem; 2017 May; 292(21):8750-8761. PubMed ID: 28396345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.
    Houben R; Ortmann S; Drasche A; Troppmair J; Herold MJ; Becker JC
    J Invest Dermatol; 2009 Feb; 129(2):406-14. PubMed ID: 18650848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma.
    Hsieh R; Nico MM; Camillo CM; Oliveira KK; Sangueza M; Lourenço SV
    Am J Dermatopathol; 2017 Feb; 39(2):104-110. PubMed ID: 28134726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.
    Jiang L; Campagne C; Sundström E; Sousa P; Imran S; Seltenhammer M; Pielberg G; Olsson MJ; Egidy G; Andersson L; Golovko A
    BMC Cancer; 2014 Nov; 14():857. PubMed ID: 25413220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
    Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
    J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
    Hong SP; Ahn SK
    Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.
    Fowles JS; Denton CL; Gustafson DL
    Vet Comp Oncol; 2015 Sep; 13(3):288-304. PubMed ID: 23745794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IQGAP1 modulates activation of B-Raf.
    Ren JG; Li Z; Sacks DB
    Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10465-9. PubMed ID: 17563371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting NRAS in melanoma.
    Kelleher FC; McArthur GA
    Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IQGAP1 mediates angiotensin II-induced apoptosis of podocytes via the ERK1/2 MAPK signaling pathway.
    Liu Y; Liang W; Yang Q; Ren Z; Chen X; Zha D; Singhal PC; Ding G
    Am J Nephrol; 2013; 38(5):430-44. PubMed ID: 24247724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas.
    Takata M; Goto Y; Ichii N; Yamaura M; Murata H; Koga H; Fujimoto A; Saida T
    J Invest Dermatol; 2005 Aug; 125(2):318-22. PubMed ID: 16098043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.